Bispecific antibodies and antibody-conjugates offer exciting opportunity to combat redundant cancer survival pathways. Our long term goal is to generate effective antibody-based reagents for cancer treatment and remission with specific interests in both solid epithelial cancers types and leukemias. In addition to the use of bispecific antibodies, we are also pursuing siRNA-based conjugates for selective cancer targeting.
Tailored fit targeting approaches: Cancer Immunotherapy, Antibodies and conjugates
Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies